The stock's fall snapped a four-day winning streak.

Eli Lilly & Co. Annual stock financials by MarketWatch. View the latest LLY financial statements, income statements and financial ratios.

Eli Lilly (NYSE:LLY) has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out among recent ...

Eli Lilly offered a 115% premium for Verve, signaling a major vote of confidence in gene editing platforms. HC Wainwright and William Blair downgraded Verve after the deal.

Boston Globe via Getty Images Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine.

Eli Lilly (LLY -2.40%) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help ...

Lilly has been busy this year acquiring the rights to medicines developed by small pharmaceutical start-ups. Most notably, it acquired Scorpion Therapeutics and its PI3Kα inhibitor program for $2 ...

Eli Lilly is on something of a tear, aiming to prove with Tuesday’s $1.3 billion acquisition of Verve Therapeutics that it’s more than just a cardio-metabolic and neuroscience company. The ...

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click for more on LLY and VERV.

It's the remarkable true story of one woman's fight for equal pay that impacts us all! Oscar-nominated actress Patricia Clarkson joined us to talk about her starring role in the new movie "Lilly ...

Reuters FILE PHOTO: The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018.